

Krishna V Komanduri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8959872/publications.pdf>

Version: 2024-02-01

154
papers

13,287
citations

66315

42
h-index

23514

111
g-index

155
all docs

155
docs citations

155
times ranked

13381
citing authors

#	ARTICLE	IF	CITATIONS
1	Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. Transplantation and Cellular Therapy, 2022, 28, 48.e1-48.e10.	0.6	18
2	Treating CAR-T relapses: check not checkmate. Blood, 2022, 139, 955-957.	0.6	2
3	Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT. Transplantation and Cellular Therapy, 2022, 28, 303.e1-303.e7.	0.6	2
4	Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2021, 39, 476-486.	0.8	8
5	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood, 2021, 137, 3291-3305.	0.6	85
6	Use of Post-transplant Cyclophosphamide Treatment to Build a Tolerance Platform to Prevent Liquid and Solid Organ Allograft Rejection. Frontiers in Immunology, 2021, 12, 636789.	2.2	3
7	National Marrow Donor Programâ€“Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. Journal of Clinical Oncology, 2021, 39, 1971-1982.	0.8	90
8	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplantation, 2021, 56, 3068-3077.	1.3	13
9	nLower incidence of Cytomegalovirus reactivation following post-transplant cyclophosphamide HLA mismatched unrelated donor transplantation. Transplantation and Cellular Therapy, 2021, 27, 1017.e1-1017.e1.	0.6	5
10	Trial in Progress: A Phase II Trial of Belinostat As Consolidation Therapy with Zidovudine for Adult T-Cell Leukemia-Lymphoma (ATLL). Blood, 2021, 138, 2477-2477.	0.6	3
11	Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation. Blood, 2021, 138, 1814-1814.	0.6	0
12	Development of a Predictive Model for Cytokine Release Syndrome to Inform Risk Stratification and CRS Management Following Immunotherapy. Blood, 2021, 138, 1459-1459.	0.6	1
13	Failure of atovaquone prophylaxis for prevention of toxoplasmosis in hematopoietic cell transplant recipients. Transplant Infectious Disease, 2020, 22, e13198.	0.7	4
14	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injuryâ€“Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open, 2020, 3, e1918668.	2.8	40
15	Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leukemia and Lymphoma, 2020, 61, 940-943.	0.6	75
16	Regulatory Issues in Gene-Modified Immune Effector Cell Therapy. , 2020, , 209-222.		2
17	Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study. Blood Advances, 2020, 4, 4618-4622.	2.5	15
18	STING differentially regulates experimental GVHD mediated by CD8 versus CD4 T cell subsets. Science Translational Medicine, 2020, 12, .	5.8	15

#	ARTICLE	IF	CITATIONS
19	Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e13866.	0.8	48
20	Successful Treatment of Invasive Fungal Infection Due to Highly Resistant <i>Aspergillus calidoustus</i> in an Allogeneic Hematopoietic Cell Transplant Recipient. <i>Mycopathologia</i> , 2020, 185, 399-403.	1.3	5
21	Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative. <i>Blood</i> , 2020, 136, 48-49.	0.6	5
22	Early antibiotic use is associated with CMV risk and outcomes following allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 6364-6367.	2.5	5
23	Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee. <i>Blood</i> , 2020, 136, 27-29.	0.6	0
24	Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 6-16.	1.3	22
25	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
26	Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13054.	0.7	5
27	Saddle Nose Deformity in an Immunosuppressed Patient. <i>Clinical Infectious Diseases</i> , 2019, 68, 705-709.	2.9	2
28	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1354-1360.	1.3	19
29	The promise of CD4 ⁺ FoxP3 ⁺ regulatory T-cell manipulation <i>in vivo</i> : applications for allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2019, 104, 1309-1321.	1.7	16
30	Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 837-848.	5.1	262
31	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. <i>Blood Advances</i> , 2019, 3, 2525-2536.	2.5	13
32	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 625-638.	2.0	1,741
33	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85
34	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1254-1265.	1.3	47
35	Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation. <i>Blood</i> , 2019, 133, 867-877.	0.6	42
36	Bloodstream Infection Due to Vancomycin-resistant <i>Enterococcus</i> Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1771-1779.	2.9	41

#	ARTICLE	IF	CITATIONS
37	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleuce (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). <i>Blood</i> , 2019, 134, 764-764.	0.6	77
38	Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. <i>F1000Research</i> , 2019, 8, 1194.	0.8	37
39	The Innate Immune Sensor Sting Promotes Donor CD8+ T Cell Activation and Recipient APC Death Early after Preclinical Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 3202-3202.	0.6	0
40	Multiple Pathways Targeting CD25 or TNFRSF25 Affect CD4+FoxP3+ Regulatory T Cell Phenotype and Suppressive Function. <i>Blood</i> , 2019, 134, 4430-4430.	0.6	0
41	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1119-1124.	2.0	33
42	Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 4-12.	2.0	6
43	Chimeric antigen receptor T-cell therapy " assessment and management of toxicities. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 47-62.	12.5	1,659
44	Divining T-cell targets for cancer immunotherapy. <i>Blood</i> , 2018, 132, 1861-1863.	0.6	1
45	Vaccinating donors for hematopoietic cell transplantation: A systematic review and future perspectives. <i>Vaccine</i> , 2018, 36, 6043-6052.	1.7	3
46	Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. <i>Blood Advances</i> , 2018, 2, 607-620.	2.5	75
47	Very Low Numbers of CD4+FoxP3+Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1788-1794.	2.0	23
48	BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT. <i>Frontiers in Immunology</i> , 2018, 9, 3104.	2.2	20
49	Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 806-814.	2.0	46
50	Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models. <i>JCI Insight</i> , 2018, 3, .	2.3	15
51	Burden and Outcomes of Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections (MBI-LCBI) in the First 100 Days after Allogeneic Stem Cell Transplant: A CIBMTR Analysis. <i>Blood</i> , 2018, 132, 3375-3375.	0.6	0
52	Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 757-766.	2.0	45
53	Innately interesting interactions. <i>Blood</i> , 2017, 130, 844-845.	0.6	1
54	Axicabtagene Ciloleuce CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	13.9	3,865

#	ARTICLE	IF	CITATIONS
55	Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 233-238.	0.6	78
56	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 870-881.	2.0	38
57	Functional Signatures Revealed By Deep Phenotyping of CMV-Specific CD8+ T Cells Predict Risk of Early CMV Reactivation after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2017, 130, 746-746.	0.6	1
58	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71
59	The use of brincidofovir for the treatment of mixed dsDNA viral infection. <i>Journal of Clinical Virology</i> , 2016, 83, 1-4.	1.6	23
60	Novel Scoring Criteria for the Evaluation of Ocular Graft-versus-Host Disease in a Preclinical Allogeneic Hematopoietic Stem Cell Transplantation Animal Model. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1765-1772.	2.0	26
61	Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification. <i>Annual Review of Medicine</i> , 2016, 67, 59-72.	5.0	42
62	The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects. <i>JCI Insight</i> , 2016, 1, e86331.	2.3	21
63	Decreases in thymopoiesis of astronauts returning from space flight. <i>JCI Insight</i> , 2016, 1, e88787.	2.3	36
64	A maturing understanding of naive T cells. <i>Blood</i> , 2015, 125, 2742-2743.	0.6	0
65	Targeting the IL-2/CD25 and TL1A/TNFRSF25 Pathways: A New Approach to Markedly Expand Donor Tregs in Multiple Compartments Leads to in Situ Immune Regulation. <i>Blood</i> , 2015, 126, 4281-4281.	0.6	0
66	A Novel Reduced-Intensity Conditioning Regimen for Unrelated Umbilical Cord Blood Transplantation in Children with Nonmalignant Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 326-336.	2.0	53
67	Immunologic Outcomes of Allogeneic Stem Cell Transplantation: Graft-Versus-Host and Graft-Versus-Leukemia Responses and Implications for Future Therapy. , 2014, , 237-273.		0
68	Antigen and Lymphopenia-Driven Donor T Cells Are Differentially Diminished by Post-Transplantation Administration of Cyclophosphamide after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1430-1438.	2.0	74
69	The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success. <i>Immunologic Research</i> , 2013, 57, 125-139.	1.3	11
70	The evolving art of hematopoietic stem cell transplantation: translational research in post-transplant immune reconstitution and immunosuppression. <i>Immunologic Research</i> , 2013, 57, 140-150.	1.3	11
71	Chemical Castration of Melanoma Patients Does Not Increase the Frequency of Tumor-specific CD4 and CD8 T Cells After Peptide Vaccination. <i>Journal of Immunotherapy</i> , 2013, 36, 276-286.	1.2	4
72	MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. <i>Blood</i> , 2013, 121, 4617-4626.	0.6	48

#	ARTICLE	IF	CITATIONS
73	Targeting neovascularization in GVHD. <i>Blood</i> , 2013, 121, 3303-3304.	0.6	2
74	GVHD protection? ThiNK iNKT cells. <i>Blood</i> , 2012, 120, 1972-1973.	0.6	2
75	American Society of Blood and Marrow Transplantation Guidelines for Training in Hematopoietic Progenitor Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1322-1328.	2.0	7
76	Vitamin D receptor upregulation in alloreactive human T cells. <i>Human Immunology</i> , 2012, 73, 693-698.	1.2	33
77	Can Treg therapy prevent GVHD?. <i>Blood</i> , 2011, 117, 751-752.	0.6	13
78	Simultaneous measurement of ERK1/2, HER2, and PhosphoERK1/2 in breast cancer cell lines by flow cytometry. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 623-628.	1.1	3
79	High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2011, 86, 954-956.	2.0	26
80	Post-Transplant Cyclophosphamide (PTC) Gvhd Prophylaxis: Kinetics of Proliferation of Donor T Cells Affects Susceptibility to PTC Administration,. <i>Blood</i> , 2011, 118, 4029-4029.	0.6	0
81	Lovastatin Inhibits T-cell Proliferation While Preserving the Cytolytic Function of EBV, CMV, and MART-1-specific CTLs. <i>Journal of Immunotherapy</i> , 2010, 33, 975-982.	1.2	10
82	Cord blood transplantation: evolving strategies to improve engraftment and immune reconstitution. <i>Current Opinion in Oncology</i> , 2010, 22, 122-129.	1.1	30
83	Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome. <i>Cancer</i> , 2010, 116, 5420-5431.	2.0	393
84	2E8 Binds to the High Affinity I-domain in a Metal Ion-dependent Manner. <i>Journal of Biological Chemistry</i> , 2010, 285, 32860-32868.	1.6	5
85	Co-engagement of $\alpha 4 \beta 1$ integrin (VLA-4) and CD4 or CD8 is necessary to induce maximal Erk1/2 phosphorylation and cytokine production in human T cells. <i>Human Immunology</i> , 2010, 71, 23-28.	1.2	16
86	Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils. <i>Blood</i> , 2010, 116, 362-362.	0.6	14
87	Post-Transplant Cyclophosphamide Treatment Ameliorates Experimental Gvhd While Permitting Lymphopenic Expansion of Non-Host Reactive Donor T Cells.. <i>Blood</i> , 2010, 116, 3751-3751.	0.6	16
88	Human Late Memory CD8+ T Cells Have a Distinct Cytokine Signature Characterized by CC Chemokine Production without IL-2 Production. <i>Journal of Immunology</i> , 2009, 183, 6167-6174.	0.4	32
89	Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. <i>Bone Marrow Transplantation</i> , 2009, 43, 685-692.	1.3	7
90	Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1513-1522.	2.0	31

#	ARTICLE	IF	CITATIONS
91	Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens. <i>Blood</i> , 2009, 113, 4213-4223.	0.6	21
92	Planning based on postneedle volume with early dosimetric assessment is beneficial for Cesium-131 permanent prostate seed implantation. <i>Brachytherapy</i> , 2008, 7, 237-241.	0.2	14
93	Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2008, 41, 63-67.	1.3	63
94	Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. <i>Bone Marrow Transplantation</i> , 2008, 41, 771-778.	1.3	233
95	362: Incidence and Risk Factors for Chronic Graft-Versus-Host Disease (cGVHD) after Cord Blood Transplantation (CBT). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 132-133.	2.0	3
96	GVHD therapy: let there be light!. <i>Blood</i> , 2008, 112, 932-933.	0.6	1
97	Deficient TH-1 Responses From TNF- α -matured and β -CD40-matured Dendritic Cells. <i>Journal of Immunotherapy</i> , 2008, 31, 157-165.	1.2	13
98	Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. <i>Blood</i> , 2008, 112, 154-154.	0.6	13
99	High Prevalence of Vitamin D Deficiency in Allogeneic Stem Cell Transplant Recipients.. <i>Blood</i> , 2008, 112, 2138-2138.	0.6	0
100	Targeting of alpha4beta1 Integrin and CD4/CD8 on Human T Cells, in Addition to CD3 and CD28, Induces Maximal Activation, as Assessed by Single-Cell Analysis of MAP Kinase Pathway Activation and Cytokine Production.. <i>Blood</i> , 2008, 112, 1538-1538.	0.6	0
101	Demonstration of a Direct Immunomodulatory Role for Vitamin D in Human T Cells Using Flow Cytometry. <i>Blood</i> , 2008, 112, 2577-2577.	0.6	0
102	Regulatory and Naïve T Cells in Unmanipulated Donor Grafts Are Not Associated with Acute Graft Vs Host Disease in Matched Sibling Transplants for AML. <i>Blood</i> , 2008, 112, 719-719.	0.6	0
103	Chronic graft-versus-host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care. <i>The Journal of Supportive Oncology</i> , 2008, 6, 361-72.	2.3	9
104	Effects of <i>Aspergillus fumigatus</i> gliotoxin and methylprednisolone on human neutrophils: implications for the pathogenesis of invasive aspergillosis. <i>Journal of Leukocyte Biology</i> , 2007, 82, 839-848.	1.5	61
105	Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. <i>Blood</i> , 2007, 110, 4543-4551.	0.6	296
106	Lymphoid Reconstruction and Vaccines. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 17-22.	2.0	12
107	269: Correlates and outcome of absolute lymphocyte count (ALC) on day 30 post allogeneic stem cell transplantation (SCT) for treatment of AML. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 98.	2.0	1
108	309: Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 112-113.	2.0	0

#	ARTICLE	IF	CITATIONS
109	349: Higher-order cytokine flow cytometry reveals distinct functional signatures of maturation subsets of CD4+ and CD8+ T cells. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 126-127.	2.0	0
110	2: Donor-Recipient Host-Versus-Graft Human Leukocyte Antigen Mismatches and Outcome of Cord Blood Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1393.	2.0	1
111	20: Delayed Immune Recovery after Umbilical Cord Blood Transplantation (UCBT) Is Characterized By Thymic Regeneration Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1400.	2.0	0
112	Dosimetric Evaluation of Radiation Exposure During I-125 Vicryl Mesh Implants: Implications for ACOSOG z4032. <i>Annals of Surgical Oncology</i> , 2007, 14, 3610-3613.	0.7	15
113	Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. <i>Bone Marrow Transplantation</i> , 2007, 40, 125-136.	1.3	117
114	PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 283-283.	0.6	9
115	PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival.. <i>Blood</i> , 2007, 110, 577-577.	0.6	5
116	AML-loaded DC generate Th1-type cellular immune responses in vitro. <i>Cytotherapy</i> , 2006, 8, 95-104.	0.3	7
117	Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. <i>Cytotherapy</i> , 2006, 8, 149-157.	0.3	37
118	Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation: Evolving Concepts and Novel Therapies Including Photopheresis. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1-6.	2.0	17
119	PR1 vaccine after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 16.	2.0	0
120	Disease status at transplant impacts lymphocyte and platelet recovery after allogeneic peripheral blood stem cell transplant (PBSCT) for patients with AML/MDS. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 42.	2.0	0
121	Optimization of expansion of cord blood T cells with anti-CD3/anti-CD28 coated beads. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 81-82.	2.0	9
122	Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. <i>Vaccine</i> , 2006, 24, 3203-3216.	1.7	32
123	Delayed Immune Recovery after Umbilical Cord Blood Transplantation (UCBT) Is Characterized by Thymic Regeneration Failure.. <i>Blood</i> , 2006, 108, 312-312.	0.6	6
124	Characterization of optimal T Cell/Dendritic Cell (DC) Co-Culture Conditions for Ex Vivo Expansion of Antigen-Specific Human T Cells.. <i>Blood</i> , 2006, 108, 3654-3654.	0.6	19
125	Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.. <i>Blood</i> , 2006, 108, 3668-3668.	0.6	5
126	Donor-Recipient Host-Versus-Graft (HVG) HLA Mismatches and Outcome of Cord Blood Transplants (CBT).. <i>Blood</i> , 2006, 108, 436-436.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. <i>Blood</i> , 2005, 105, 2258-2265.	0.6	183
128	Prescription dose in permanent Cs131 seed prostate implants. <i>Medical Physics</i> , 2005, 32, 2496-2502.	1.6	16
129	Detection of Gliotoxin in Experimental and Human Aspergillosis. <i>Infection and Immunity</i> , 2005, 73, 635-637.	1.0	171
130	Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 108-114.	2.0	109
131	Cell-Autonomous Upregulation of Dendritic Cell Immunocompetence Is Antigen-Dependent.. <i>Blood</i> , 2005, 106, 2230-2230.	0.6	1
132	Superior Acute Myeloid Leukemia-Specific T Cell Responses Using Dendritic Cells Pulsed with Apoptotic Bodies, vs.Tumor Lysates or mRNA.. <i>Blood</i> , 2005, 106, 295-295.	0.6	1
133	Vaccines in Leukemia. <i>Advances in Pharmacology</i> , 2004, 51, 255-270.	1.2	5
134	Acute graft-versus-host disease: Pathophysiology, clinical manifestations, and management. <i>Cancer</i> , 2004, 101, 1936-1946.	2.0	195
135	Intraarterial Platelet Infusion for Patients with Intractable Gastrointestinal Hemorrhage and Severe Refractory Thrombocytopenia. <i>Journal of Vascular and Interventional Radiology</i> , 2004, 15, 393-397.	0.2	9
136	GVHD therapy: the best-laid schemes.... <i>Blood</i> , 2004, 104, 1240-1241.	0.6	1
137	CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. <i>Blood</i> , 2004, 103, 1140-1146.	0.6	85
138	Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. <i>Blood</i> , 2004, 104, 3429-3436.	0.6	77
139	Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia.. <i>Blood</i> , 2004, 104, 259-259.	0.6	47
140	A Model to Predict Risk for Late Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation for Hematological Malignancies.. <i>Blood</i> , 2004, 104, 2241-2241.	0.6	0
141	Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. <i>Current Opinion in Hematology</i> , 2002, 9, 503-508.	1.2	49
142	Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. <i>Blood</i> , 2002, 100, 3690-3697.	0.6	196
143	Thymic function and allogeneic T-cell responses in stem-cell transplantation. <i>Cytotherapy</i> , 2002, 4, 333-342.	0.3	8
144	Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. <i>British Journal of Haematology</i> , 2002, 119, 773-776.	1.2	76

#	ARTICLE	IF	CITATIONS
145	Direct Measurement of CD4+ and CD8+ T-Cell Responses to CMV in HIV-1-Infected Subjects. <i>Virology</i> , 2001, 279, 459-470.	1.1	92
146	Loss of Cytomegalovirus-Specific CD4+T Cell Responses in Human Immunodeficiency Virus Type 1-Infected Patients with High CD4+T Cell Counts and Recurrent Retinitis. <i>Journal of Infectious Diseases</i> , 2001, 183, 1285-1289.	1.9	112
147	Direct Evidence for Thymic Function in Adult Humans. <i>Journal of Experimental Medicine</i> , 1999, 190, 479-486.	4.2	218
148	Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. <i>Nature Medicine</i> , 1998, 4, 953-956.	15.2	395
149	Interleukin-8 Inhibits Non-Small Cell Lung Cancer Proliferation: A Possible Role for Regulation of Tumor Growth by Autocrine and Paracrine Pathways. <i>Journal of Interferon and Cytokine Research</i> , 1996, 16, 53-60.	0.5	54
150	The Natural History and Molecular Heterogeneity of HIV-Associated Primary Malignant Lymphomatous Effusions. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 13, 215-226.	0.3	105
151	Effects of Transforming Growth Factor-beta on Human Pulmonary Adenocarcinoma Cell Adhesion, Motility, and Invasion In Vitro. <i>Journal of the National Cancer Institute</i> , 1992, 84, 523-527.	3.0	75
152	Pathology of Hematopoietic Stem Cell Transplantation. , 0, , 260-293.		0
153	Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. <i>F1000Research</i> , 0, 8, 1194.	0.8	33
154	Development and Reconstitution of T-Lymphoid Immunity. , 0, , 79-107.		1